Flavonoid · Senolytic · Natural

Fisetin: The Natural Senolytic

A strawberry-derived flavonoid that clears senescent ("zombie") cells — the accumulated cellular debris implicated in aging, inflammation, and age-related disease.

🔬 Fisetin is HighPeptides' entry-point senolytic because it's OTC, well-tolerated, and doesn't require the dasatinib prescription route.

Standard Senolytic Dose

Hit-and-Run Protocol

Flavonoid Potency Rank

Mechanism of Action

How It Works

🧟

Senescent Cell Clearance

Fisetin selectively triggers apoptosis in senescent cells while sparing healthy ones — demonstrated in 2018 Mayo Clinic mouse studies showing extended healthspan and lifespan.

🛡️

SIRT1 & Sirtuin Activation

Activates sirtuin family deacetylases implicated in longevity pathways. Mechanism overlap with resveratrol but stronger senolytic effect per dose.

🧠

BDNF + Neuroprotection

Crosses the blood-brain barrier, elevates BDNF, reduces microglial senescence in aged rodents. Candidate for cognitive-aging protocols.

🔥

Anti-Inflammatory

Reduces NF-κB signaling and senescence-associated secretory phenotype (SASP) — the inflammatory soup that senescent cells release into surrounding tissue.

Data

What the Data Shows

Senescent cell reduction (mice, adipose)

Mayo Clinic 2018, 20mg/kg fisetin

-25%

BDNF elevation (aged mice, cortex)

Dose-dependent, 7-day loading

+40%

SASP cytokines (IL-6, TNF-α)

Reduction after senolytic treatment

~-35%

Human clinical trial data

Phase 2 at Mayo still reporting — human efficacy data pending

Limited

Bottom Line

Key Takeaways

✅ What We Know

Strongest natural senolytic identified in screening assays — 10x more potent than quercetin
Excellent oral bioavailability compared to most flavonoids
Well-tolerated at high doses in humans (no dose-limiting toxicity found in Phase 2 trials)
Crosses the blood-brain barrier — unusual for flavonoids
Mouse lifespan extension ~10% in Mayo Clinic studies with intermittent dosing

⚠️ What We Don't Know

Human efficacy endpoints are still pending — mouse → human translation uncertain for senolytics
Optimal dosing protocol not established for humans (hit-and-run vs. chronic low-dose)
Commercial products vary in bioavailability (lipid-encapsulated formulations may work better)
Long-term (decade+) safety data does not exist
Stacking with dasatinib+quercetin may be more effective but also more risky

FAQ

Frequently Asked Questions

What is the senolytic protocol?

Most protocols use a "hit-and-run" approach: 20mg/kg orally for 2 consecutive days, once per month. This mirrors the Mayo Clinic mouse dosing and gives senescent cells time to clear without chronic exposure.

How does fisetin compare to dasatinib + quercetin?

Dasatinib+quercetin (D+Q) is the most-studied senolytic combo but dasatinib is a leukemia drug with real side effects. Fisetin alone is safer and OTC but single-compound senolytic effects are typically weaker than combos.

Is fisetin safe long-term?

Short-term safety is well-established. Long-term (years) human safety at senolytic doses has not been studied. Most intermittent protocols assume safety by limiting exposure.

Do I need the lipid-encapsulated version?

Liposomal or lipid-encapsulated fisetin has dramatically better bioavailability. Standard fisetin powder is absorbed poorly. For senolytic doses, the encapsulated forms are worth the premium.